![]() Information comparing the risks and benefits of aspirin. GPs were presented with one of eight versions of a patient vignette, manipulating the presence or absence of three types of information on the effectiveness of aspirin for colorectal cancer prevention: The optimal type and level of information to communicate with GPs was investigated to increase their willingness to prescribe aspirin to a patient with LS. 5 In the present study, the relative effects of these different, potentially modifiable, influences on decisions to prescribe aspirin for patients with LS were evaluated in light of the new NICE guidance. 7 In addition, a large UK survey found GPs who were more aware of aspirin’s cancer preventive benefits were more willing to prescribe the medication to a patient with LS. 6 An Australian interview study identified several barriers among healthcare professionals about prescribing aspirin for colorectal cancer prevention, including concerns about side effects, limited awareness of the national guidance, and uncertainties about the strength of evidence. 5 Ideally, strategies to change clinical practice should be informed by an understanding of the barriers to prescribing behaviour. 4Īspirin prescribing is likely to occur in primary care, but GPs may be reluctant to do so. 4 NICE did not recommend a dose, but 150–300 mg are commonly used in practice. 3 In 2020, the National Institute for Health and Care Excellence (NICE) NG151 guideline for colorectal cancer management recommended considering daily aspirin to reduce colorectal cancer risk in people with LS. 2 The CAPP2 trial observed a reduced risk of colorectal cancer among people with LS randomised to 600 mg aspirin versus placebo at 10 years (hazard ratio 0.65, 95% confidence interval = 0.43 to 0.97). 1 Aspirin has been investigated as a preventive therapy for colorectal cancer. Lynch syndrome (LS) is an inherited condition that increases the risk of developing several cancers, including colorectal cancer.
0 Comments
Leave a Reply. |